Lexicon Pharmaceuticals (LXRX) Return on Capital Employed (2011 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Return on Capital Employed data on file, last reported at 11.16% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 8356.0% year-over-year to 11.16% in Q1 2026; TTM through Mar 2026 was 11.16%, a 8356.0% increase from a year earlier, with the FY2025 full-year figure at 22.15%, up 6799.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 11.16%, up from 28.01% in the prior quarter.
• Over the last five years, Return on Capital Employed for LXRX reached as high as 11.16% in Q1 2026 and fell as low as 94.72% in Q1 2025.
• Historically, Return on Capital Employed has averaged 61.18% across 5 years, with a median of 62.0% in 2024.
• Across the five-year window, Return on Capital Employed plunged 11610 bps in 2022 and surged 8356 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 59.33% in 2022, then plunged by 31 bps to 77.57% in 2023, then gained by 4 bps to 74.52% in 2024, then soared by 62 bps to 28.01% in 2025, then jumped by 60 bps to 11.16% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 11.16% in Q1 2026, 28.01% in Q4 2025, and 34.46% in Q3 2025.